



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: Protocol Development and Regulatory Compliance

DATE: April 21, 2023

RE: PROTOCOL NRG-GI007 – TEMPORARILY CLOSED TO ACCRUAL

NRG-GI007, “Phase I Trial With Expansion Cohort of OBP-301 (Telomelysin™) and Definitive Chemoradiation for Patients With Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery,” is temporarily closed to accrual **effective immediately** because target accrual to the initial dose level has been met.

The trial will be temporarily closed for approximately 3 months for a protocol-specified toxicity analysis. When accrual is ready to be resumed, NRG Oncology will send a reopening notice.

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate institutions.